Schering Hunting Biotech Deals To Complement Specialty Portfolio

Schering-Plough is focusing its in-licensing activities on specialty biotechnology products, CEO Fred Hassan told analysts during the company's business review in New York City Nov. 18

More from Archive

More from Pink Sheet